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Abstract
Multidrug resistance (MDR) is a major impediment to curative cancer chemotherapy. The ATP-Binding Cassette transporters
ABCG2, ABCB1 and ABCC2 form a unique defense network against multiple structurally and functionally distinct
chemotherapeutics, thereby resulting in MDR. Thus, deciphering novel mechanisms of MDR and their overcoming is a major
goal of cancer research. Recently we have shown that overexpression of ABCG2 in the membrane of novel extracellular
vesicles (EVs) in breast cancer cells results in mitoxantrone resistance due to its dramatic sequestration in EVs. However,
nothing is known about EVs structure, biogenesis and their ability to concentrate multiple antitumor agents. To this end, we
here found that EVs are structural and functional homologues of bile canaliculi, are apically localized, sealed structures
reinforced by an actin-based cytoskeleton and secluded from the extracellular milieu by the tight junction proteins occludin
and ZO-1. Apart from ABCG2, ABCB1 and ABCC2 were also selectively targeted to the membrane of EVs. Moreover, Ezrin-
Radixin-Moesin protein complex selectively localized to the border of the EVs membrane, suggesting a key role for the
tethering of MDR pumps to the actin cytoskeleton. The ability of EVs to concentrate and sequester different antitumor
drugs was also explored. Taking advantage of the endogenous fluorescence of anticancer drugs, we found that EVs-forming
breast cancer cells display high level resistance to topotecan, imidazoacridinones and methotrexate via efficient
intravesicular drug concentration hence sequestering them away from their cellular targets. Thus, we identified a new
modality of anticancer drug compartmentalization and resistance in which multiple chemotherapeutics are actively
pumped from the cytoplasm and highly concentrated within the lumen of EVs via a network of MDR transporters
differentially targeted to the EVs membrane. We propose a composite model for the structure and function of MDR pump-
rich EVs in cancer cells and their ability to confer multiple anticancer drug resistance.
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Introduction
The frequent emergence of drug resistance phenomena to
structurally and functionally unrelated anticancer drugs known as
multidrug resistance (MDR) continues to be a major impediment
to curative cancer chemotherapy [1,2,3,4,5,6]. Members of the
ATP-Binding Cassette (ABC) superfamily of transporters including
ABCB1 (P-gp), ABCC1 (MRP1) and ABCG2 (BCRP) function as
ATP-dependent MDR efflux transporters. These multidrug
extrusion pumps form a unique defense network against multiple
chemotherapeutic drugs, as well as endogenous and exogenous
cellular toxicants. We have recently found that in mitoxantrone
(MR)-resistant MCF-7 breast cancer cells (MCF-7/MR) [7],
ABCG2 is overexpressed and confined to cell-cell attachment
zones, where ABCG2-rich extracellular vesicles (EVs) are formed
[8]. Shared by neighbor cells, these EVs display a 1000-fold
intravesicular concentration of MR when compared to its
concentration in the culture medium, thereby resulting in MR
resistance. Moreover, inhibition of ABCG2 transport activity with
the specific transport inhibitors Ko143 and fumitremorgin C
(FTC) abolished intravesicular MR accumulation, hence resulting
in restoration of drug sensitivity.
In spite of the important implications of these drug-concentrat-
ing EVs for cancer chemotherapy, nothing is known about their
structure, biogenesis and ability to sequester multiple anticancer
drugs. Towards this end, we here explored the possible association
of cytoskeletal components characteristic of polarized epithelia
including tight junction (TJ) proteins, actin and microtubule
filaments as well as Ezrin-Radixin-Moesin (ERM) complex
proteins with the membrane of EVs. TJ proteins have three
mutually exclusive functions; a fence function which differentiates
between proteins of the apical and basolateral membranes, a gate
function which controls the paracellular passage of ions and solutes
in-between epithelial and endothelial cells, as well as a bridge
function which facilitates the communication between neighboring
cells [9,10]. Proteins of the ERM complex are closely related
polypeptides linking actin filaments to the plasma membrane
either directly via binding to the cytoplasmic tail of membrane
proteins, or indirectly via scaffold proteins attached to membrane
proteins [11].
Here we show that EVs are apically localized and reinforced by
cytoskeletal proteins. We provide evidence for the role of TJ
proteins including occludin and ZO-1 in the formation of sealed
EVs that are secluded from the extracellular milieu. We further
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contains the major MDR efflux transporters ABCB1 and ABCC2,
thereby highly concentrating multiple anticancer drugs in the
lumen of EVs. Furthermore, the ERM protein complex was found
to be selectively targeted to the EV membrane, suggesting a
functional role in the cross-linking of these MDR pumps to the
actin cytoskeleton. Hence, a new modality of MDR is described
here in which ABC transporters that are selectively sorted out to
the membrane of EVs, actively pump and sequester multiple
anticancer drugs within the EV lumen, thereby resulting in a
marked chemoresistance.
Results
TJ proteins are involved in the formation of EVs that
mediate MDR
Previously we have shown that ABCG2-rich EVs of breast
cancer cells concentrate riboflavin and MR by factors of 560- and
1000-fold, respectively, when compared to their concentration in
the extracellular medium [8,12]. To identify proteins that may
contribute to the formation of these ostensibly sealed EVs,
immunofluorescence microscopy was performed using antibodies
specific to TJ proteins; this included occludin as a major TJ-
forming protein which mediates cell-cell adhesion and ZO-1 as a
representative TJ-associated protein that crosslinks TJs to the
actin-cytoskeleton [13,14]. MCF-7/MR cells were co-stained with
antibodies to ABCG2 which served as a specific biomarker for
EVs, as well as with ZO-1 (Figure 1A–1C) and occludin
(Figure 1D–1F). Both ZO-1 and occludin displayed intense
localization at cell-cell attachment zones, albeit occludin also had
some cellular staining. These TJ proteins surrounded ABCG2-rich
EVs, hence forming intense ring structures precisely at the border
of EVs-forming cells. When a single EV is formed by two attached
cells, one belt-like structure was located between these neighboring
cells. Other EVs had several belt-like structures around them,
indicating that three or more attached cells participated in EV
formation (Figure 1). A small fraction (,8.5%) of vesicular
structures was found to be positive for ABCG2 but showed no
discernible staining for ZO-1 and appeared to be intracellular (i.e.
vacuoles; data not shown). Parental MCF-7 cells (ATCC number
HTB-22), which are characterized by very low ABCG2 protein
levels [8] and rarely form EVs (which are much smaller than in
MCF-7/MR cells), exhibited consistent TJ localization to the EVs
membrane (Supplementary Figure S1).
EVs are formed at the apical pole of MCF-7/MR cells
During the current study we observed a strong similarity
between the EVs that form in breast cancer cells and bile
canaliculi, previously described in polarized WIF-B9 [15] and
HepG2 [16] cells. We hence theorized that EVs are apically
localized. To test this hypothesis, we ectopically overexpressed
GPI-CFP and VSVG-YFP constructs which are harboring
established apical and basolateral markers proteins, respectively
[17,18]. Expectedly, ABCG2, an established EV membrane
marker co-localized with the apical GPI marker (Figure 2A–
2F); in contrast, the basolateral marker VSVG was equally
distributed in the cell membrane and did not display an exclusive
co-localization with ABCG2, an EV membrane marker
(Figure 2G–2L).
Selective targeting of MDR transporters to the membrane
of EVs. Endogenous ABCG2 is overexpressed in MCF-7/MR
cells and is targeted differentially to the membrane of EVs [8].
However, in MCF-7/MR cells which are not part of a colony
and/or that do not participate in the formation of EVs, ABCG2
Figure 1. Specific targeting of TJ proteins ZO-1 and occludin to
EVs in MCF-7/MR cells. MCF-7/MR cells were grown for 7 days to
allow for the formation of EVs, fixed and co-reacted with monoclonal
antibodies to ABCG2 (A, BXP-53; D, BXP-21), ZO-1 (B) and occludin (E).
Panels C and F are merged photographs of A and B as well as D and E,
respectively. White arrows denote the localization of TJ proteins,
whereas dashed arrows represent EVs. Cells were examined with a Zeiss
inverted Cell-Observer microscope at a magnification of 6630. The
merged images, including nuclei stained with DAPI, were generated
using Cell-Observer software to illustrate the three-dimensional
architecture of EVs. Throughout the entire study the bar denotes10mm.
doi:10.1371/journal.pone.0016007.g001
Figure 2. Apical localization of EVs in MCF-7/MR cells. Cells were
transiently transfected with GPI-CFP and VSVG-YFP constructs (green
fluorescence), reacted with anti-ABCG2 antibody BXP-53 (red fluores-
cence) and DAPI and analyzed using Zeiss inverted Cell-Observer
microscope at a magnification of 6630. Arrows denote the subcellular
localization of GPI-CFP (A–F) and VSVG-YFP (G–L).
doi:10.1371/journal.pone.0016007.g002
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Figure S2 G–I, continuous arrows). Based on the localization
pattern of TJ proteins to cell-cell contact sites of EVs-forming cells
(Figure 1 and supplementary Figure S1), we hypothesized
that there may be a physical separation of the EV membrane from
the cell membrane. To examine this hypothesis we first stably
overexpressed an ABCG2-EGFP construct in parental MCF-7
and MCF-7/MR cells. Ectopic overexpression of ABCG2-EGFP
resulted in differential transporter targeting in parental and drug
resistant cells; in parental MCF-7 cells, which infrequently form
EVs, ABCG2-EGFP localized primarily at the cell membrane
(Supplementary Figure S2 A–C). However, when EVs
infrequently formed in MCF-7 cells, ABCG2-EGFP was targeted
to the EVs membrane. In contrast, in MCF-7/MR cells, ABCG2-
EGFP was targeted exclusively to the membrane of EVs and cell-
cell attachment zones (Supplementary Figure S2 D–F). Thus,
we focused our further studies on MCF-7/MR cells in an attempt
to explore the possible differential sorting of various MDR efflux
transporters of the ABC superfamily including ABCB1, ABCC1,
ABCC2 and ABCC3 (i.e. P-gp, MRP1, MRP2 and MRP3,
respectively) to the EV membrane. These ATP-driven MDR efflux
transporters differ markedly in substrate specificity, tissue
distribution and intracellular localization [1,4,5,6]. Previously we
have shown that ABCC2 and ABCC3 levels are undetectable in
MCF-7/MR cells, whereas low levels of ABCC1 were present
[19]. To determine the targeting specificity of these ABC
transporters to the EV membrane, we introduced these MDR
transporter genes into MCF-7/MR cells and determined their sub-
cellular localization by immunofluorescence microscopy. ABCB1
and ABCC2 were specifically targeted to the EV membrane and
to cell-cell attachment zones, hence perfectly co-localizing with
ABCG2 (Figure 3A–3C and 3D–3I, respectively). Analysis of
ABCB1- and ABCC2-transfectant cells revealed that some EVs
displayed a unique transporter co-localization pattern with
ABCG2 and the exogenously transfected transporter solely
present in one half of the EV membrane (Figure 3A–3C and
3D–3F arrows), whereas other EVs exhibited an equally distributed
co-localization pattern (Figure 3G–3I). In contrast, in ABCC1-
(Figure 2J–3L) and ABCC3-transfected (Figure 3M–3O) MCF-
7/MR cells, these MDR transporters were equally targeted to the
cell membrane. The proton-coupled folate transporter (PCFT/
SLC46A1), which is representative of various proton-coupled low
pH carriers, that mediate intestinal absorption of various essential
nutrients [20,21,22], was further examined. Consistent with
previous findings [22,23], PCFT, the dominant intestinal folate
transporter [22], was targeted to the entire cell membrane of
MCF-7/MR cells, thus no co-localization of PCFT and ABCG2
was found in the EVs membrane (Figure 3P–3R). The
subcellular localization of Na
+/K
+ ATPase was also determined
using immunohistochemistry and confocal laser microscopy, as
this central ATP-driven cation pump is ubiquitously expressed at
high levels and targeted to the basolateral membrane of secretory
epithelial cells including the intestine, glands and kidney [24].
Na
+/K
+ ATPase was targeted to the cell membrane of MCF-7/
MR cells, but not to the membrane of EVs (Supplementary
Figure S3 and supplementary Video S2).
The ERM protein complex selectively localizes to the
border of the EV membrane
Based on the above findings we further hypothesized that the
EV membrane residents ABCG2, ABCB1 and ABCC2 may be
anchored to the cytoskeleton via proteins of the ERM complex
[11,25]. To this end, immunofluorescence microscopy was
performed using monoclonal antibodies to ERM proteins and
ABCG2 (Figure 4). ERM proteins exclusively co-localized with
ABCG2 at the EV membrane in both MCF-7/MR (Figure 4A–
4C) and their parental MCF-7 cells (Figure 4D–4F). The mean
percentage of co-localization of ERM proteins and ABCG2 in EVs
was determined; analysis of 4,000 MCF-7/MR cells harboring 860
Figure 3. Specific targeting of transiently transfected ABCB1
and ABCC2 to the EVs membrane in MCF-7/MR cells. Cells were
transfected with ABC transporters as described in Materials and
Methods, and then studied by immunofluorescence microscopy. Shown
are the subcellular localizations of ABCB1 (A–C), ABCC1 (J–L), ABCC2 (D–
I), ABCC3 (M–O), and PCFT (P–R), when compared to that of ABCG2.
ABCG2 was followed using the monoclonal antibodies BXP-21 (J) or
BXP-53 (A, D, G, M and P). Ectopically expressed proteins are indicated
on the top of each panel. Cells were examined using either a Leica
(6400) or the Cell-Observer (6630) microscopes. Arrows denote the
location of ABCG2-rich premature and mature EVs.
doi:10.1371/journal.pone.0016007.g003
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ABCG2 in the EV membrane. Western blot analysis of ERM
protein expression revealed that in spite of the spectrum-wide
different patterns of EVs shapes and sizes in MCF-7 and MCF7/
MR cells, ERM protein localization (Figure 4A–4F) and
expression levels (Figure 4G) were identical in both cell lines.
Cytoskeletal proteins, actin and microtubules reinforce
the EVs structur
To characterize cytoskeletal proteins that may reinforce the oval
shape of EVs, we studied the subcellular localization pattern of F-
actin in relation to EVs in MCF-7/MR cells (Figure 5A). In
addition to its expected localization to cell-cell attachment zones
and its co-localization with ZO-1, F-actin was highly targeted to
the periphery of the EVs membrane, thus forming an actin-rich
brush border characteristic of the apical side of polarized epithelia
[26]. Furthermore, confocal microscopy confirmed that vesicular
F-actin was radiating from the cytoplasmic face of vesicle-forming
cells towards the vesicular membrane (Supplementary Video
S1). Hence, the possibility that F-actin resides in the lumen of EV
was ruled out.
To examine the possible roles of actin polymerization in the
biogenesis of EVs and endocytosis of transmembrane proteins,
MCF-7/MR cells were treated with cytochalasin D (CytD), a
potent mycotoxin inhibitor of actin polymerization which disrupts
microfilaments [27]. Upon CytD treatment, immunofluorescence
microscopy revealed that actin predominantly appeared as small
aggregates rather than actin filaments, and cell membrane
localization of actin was markedly reduced (Figure 5B, d–f).
However, ZO-1 was retained in cell-cell attachment zones, hence
implying that actin is presumably not the sole cytoskeletal protein
supporting vesicular structure. This pulse treatment with CytD
had no effect on ABCG2 localization to the EVs membrane
(Figure 5C). Consistently, CytD had no deleterious effect on the
highly concentrative transport function of vesicular ABCG2 as
revealed by the intense riboflavin fluorescence accumulated within
the lumen of EVs in MCF-7/MR cells (Figure 5D).
Based on our previous observation that EVs are dynamic
structures that are easily disrupted upon standard trypsinization, we
theorized that inhibition of microtubule polymerization may
interfere with EVs formation and/or with vesicular trafficking of
transmembrane proteins including ABCG2. To test this hypothesis,
we first examined the distribution pattern of microtubules in
relation to EVs location. In contrast to the localization pattern of
actin filaments, there was no significant accumulation of microtu-
bules around EVs (Figure 6A–6C). Microtubules were highly
concentrated in the vicinity of EVs and appeared as radiating out
both towards the cell membrane andthenucleus. We therefore used
nocodazole, an established inhibitor of microtubule polymerization,
which abolishes apical trafficking of proteins [16,28]. Treatment
with nocodazole resulted in disruption of the fine microtubular
network that was observed in untreated cells. However, localization
of the EV biomarkers ABCG2 and ERM complex proteins was not
significantly affected (Figure 6D–6F; 6J–6L respectively). We
hence quantified the co-localization of ABCG2 and ERM proteins
to the surface of EVs prior to, and following treatment with
nocodazole (Figure 6 M). Mean fluorescence intensity of ABCG2
and ERM proteins that localize to EVs (normalized to vesicular
area) was not affected by nocodazole treatment. The relatively large
SD observed with ABCG2 analysis is due to the fact that MCF-7/
MR cells were established by pulse exposure to MR, thus resulting
in a heterogeneous cell population with a large Gaussian
distribution of ABCG2 expression (Supplementary Figure S4)
and function [19]. Indeed, flow cytometric analysis of surface
expression of ABCG2 in viable cells confirmed the large Gaussian
distribution of ABCG2 expression in MCF-7/MR cells and
ABCG2-overexpressing A549/K1.5 non-small lung cancer cells
(Supplementary Figure S4).
Formation of EVs in various human malignant tumor cell
lines. The existence of EVs in tumor cells other than the MCF-
7/MR breast cancer subline was previously identified in our recent
paper with the ABCG2-overexpressing non-small lung cancer
A549/K1.5 cells [12]. Thus, we next explored the possible
formation of EVs in additional human malignant tumor cell lines
including gastric carcinoma N-87 cells that lack ABCG2
expression and flavopiridol-resistant breast cancer MCF-7/
FLV1000 cells with ABCG2 overexpression. Strikingly, these
carcinoma cell lines which are of distinct cell lineage formed EVs
that were identified using vesicular markers; in N-87 cells, EVs
were identified using an antibody to the ERM complex
(Figure 7A), whereas EVs in MCF-7/FLV1000 cells were
identified with antibodies to both ABCG2 and ERM complex
(Figure 7B). Moreover, EVs from both cell lines exhibited a
structure that is sealed by tight junctions (Figure 7b in A and B).
Interestingly, A549/K1.5 [12] and MCF-7/FLV1000 cells also
exhibited an ABCG2 function similar to MCF-7/MR cells; they
showed a marked accumulation of riboflavin in EVs, whereas EVs
from N-87 cells were completely devoid of riboflavin
accumulation, which is consistent with the undetectable levels of
ABCG2 in these cells (data not shown).
EVs mediate resistance to multiple anticancer drugs
The ability of ABCG2-rich EVs to concentrate and sequester
various anticancer drugs within the vesicular lumen was explored.
Towards this end, we first examined the natural chromophoric
Figure 4. Subcellular localization of the ERM protein complex
in MCF-7 and MCF-7/MR cells. MCF-7/MR (A–C) and MCF-7 cells (D-
F) were co-reacted with antibodies to ABCG2 (BXP-21, A and D) and
ERM (B and E). Random colonies were analyzed under Zeiss inverted
Cell-Observer microscope at a magnification of 6630. Western blot
analysis of ERM levels in MCF-7 and MCF-7/MR cells (G).
doi:10.1371/journal.pone.0016007.g004
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stabilizing a covalent topoisomerase I-DNA complex, thereby
inflicting a hindrance to the progression of DNA replication fork
with subsequent formation of lethal DNA lesions [29]. Topotacan
is an established ABCG2 substrate [30,31,32] and is currently
approved for the treatment of various cancers. MCF-7/MR cells
grown in a riboflavin-deficient medium to avoid its intense
intravesicular green fluorescence [12], were incubated with
topotecan (5mM) in the presence or absence of the specific
ABCG2 transport inhibitor FTC. Taking advantage of its
endogenous fluorescence, topotecan was found to highly accumu-
late in EVs in an ABCG2-dependent manner (Figure 8A).
Consequently, MCF-7/MR cells displayed 25-fold resistance to
topotecan, when compared to their parental MCF-7 cells; this
resistance was fully reversed by the ABCG2 transport inhibitor
FTC (Figure 8B). In addition to topotecan, we performed similar
accumulation experiments using viable cell fluorescence micros-
copy studies with additional fluorescent compounds which are
cytotoxic agents with distinct structure and mode of action (as well
as non-toxic compounds including riboflavin); these included
established ABCG2 substrates and non-ABCG2 substrates. The
results of the accumulation in EVs are summarized in Table 1;
whereas established chromophoric ABCG2 cytotoxic substrates
accumulated in EVs, non-ABCG2 substrates failed to accumulate
in EVs. These results highlight the remarkable capacity of
ABCG2-rich EVs to markedly sequester various anticancer drugs.
Discussion
Based on our present findings and on our previous studies with
EVs in MCF-7/MR cells [8,12], we propose a composite model for
the structure and function of ABCG2-rich EVs, and their ability to
confer resistance to multiple anticancer drugs (Figure 9). Two or
more attached cells form a tightly sealed extracellular compartment
termed EV. The oval-shape structure of this EV is reinforced by
actin microfilament-based cytoskeleton, thus forming an actin-rich
brush border at the apical side of MCF-7/MR cells. Moreover, as
would be expected from a compartment that highly concentrates
multiple chemotherapeutics, EVs are secluded from the extracel-
lular milieu by TJ proteins including occludin and ZO-1, which
localize at the border between EV-forming cells, in a belt-like
pattern. Each EV-forming cell contributes its relative share of the
vesicular structure; e.g. when three attached cells form a common
EV, three distinct belt-like structures of TJ proteins are apparent.
ABCG2 is overexpressed and selectively targeted to the EV
membrane. This unique localization of ABCG2 mediates the
efficient pumping and hence concentration of multiple cytotoxic
agents of distinct structure and mode of action (as well as non toxic
compounds including riboflavin) from the cytoplasm into the lumen
of EVs. These cytotoxic agents include topotecan, imidazoacridi-
nones, methotrexate, MR and Hoechst 33342, hence representing
various families of anticancer drugs. Most importantly, we further
discovered that apart from ABCG2, key MDR efflux transporters
Figure 5. Localization of F-actin in MCF-7/MR cells and inhibition of actin polymerization by CytD. (A) Cells grown for 7 days on glass
cover slips were fixed, permeabilized with Triton-X-100 and reacted with anti-ZO-1 antibody (a and d) and with rhodamine phalloidin (b and e) to
follow F-actin. The localization of actin and ZO-1 at the EVs surface is shown for EVs formed between two (a–c) and/or multiple attached cells (d–f).
Arrows denote the localization of cell-cell attachment zones (belt-like structures). (B) Cells were either untreated (a–c) or treated with CytD (10 mg/ml)
for 30 min at 37uC (d–f), washed and reacted as in panel A, to visualize ZO-1 (a and d) and F-actin (b and e). (C) Cells were treated as described in
panel B and then stained for ABCG2 (a and d) and F-actin (b and e). (D) Cells were grown in riboflavin (B2)-deficient medium for 48 hr prior to CytD
treatment to avoid riboflavin accumulation in EVs. Cells were then washed and transferred to riboflavin-containing medium for an additional 24 hr to
examine the riboflavin accumulation capacity (a–c). Untreated cells grown continuously in medium containing (d–f) or lacking riboflavin (g–i) served
as controls. Arrows denote the location of EVs. Cells were analyzed using a Zeiss inverted Cell-Observer microscope at a magnification of6630 (A–C)
or 6200 (D). The merged images including DAPI staining (panels A–C), were generated using Cell-Observer software.
doi:10.1371/journal.pone.0016007.g005
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EV membrane. Moreover, this differential targeting to the EVs
membrane cannot be considered a general default phenomenon for
all transporters, since ABCC1, ABCC3 and PCFT were targeted to
the cell membrane but not to the EVs membrane. Likewise, Na
+/
K
+ ATPase was directed to the cell membrane. We also found here
that ERM proteins displayed a remarkably differential sorting to,
and high abundance in the EV membrane border, thereby
suggesting a functional role for the anchoring of EV-targeted
transporters to the actin cytoskeleton. Hence, the formation of
sealed EVs shared by attached breast cancer cells and the specific
targeting of a network of MDR efflux transporters to the EV
membrane is a novel modality of anticancer drug compartmental-
ization and consequent MDR. In this respect, a variety of cytotoxic
ABCG2 transport substrates that enter cells by diffusion or via
carrier-mediated transport, are extracted from the cytoplasm and
actively pumped into the vesicular lumen by ABCG2.
The current study suggested a structural and functional
homology between the EVs of MCF-7/MR breast cancer cells
and bile canaliculi. First, the localization pattern of TJ proteins
observed in EVs was precisely that previously described for WIF-
B9 [15] and HepG2 cells [16], both of which form bile canaliculi
and target ABCB1, ABCC2, ABCG2 and ABCB11 (BSEP, bile
salt excretory protein) to the canalicular membrane [33,34,35].
This unique localization of TJ proteins could possibly function as a
gate which controls the passage of ions and solutes between the
cytoplasm and the vesicular lumen, and as a fence which
differentiates between transmembrane proteins of the apical and
basolateral membranes. Thus, ABCB1, ABCC2 and ABCG2,
which are the predominant characteristic transporters of polarized
bile canaliculi and hepatocytes [36,37], were consistently and
selectively sorted to the EVs membrane. Second, just like polarized
Figure 6. Involvement of microtubules in the formation of EVs
in MCF-7/MR cells and inhibition of microtubule polymeriza-
tion by nocodazole. MCF-7/MR cells were either untreated (A–C and
G–I) or treated with nocodazole (33 mM) for 1 hr at 37uC (D–F and J–L).
Microtubules were visualized using mouse anti b-tubulin antibody
followed by incubation with FITC-conjugated donkey anti-mouse IgG
(B, E, H and K). Cells were co-reacted with antibodies to ABCG2 (BXP-53,
A and D) or ERM (G and J), processed and analyzed as in Fig. 5 legend.
Quantification of ABCG2 and ERM protein expression on the surface of
EVs prior to and following treatment with nocodazole (M); random
fields stained as in upper panels were photographed using the same
exposure conditions for untreated and nocodazole-treated cells. The
surface area of EVs and its relative fluorescence intensity were
estimated using the AxioVision program. The fluorescence at the EVs
surface indicated protein levels at the EVs membrane. A total of 100 EVs
were analyzed for each examined protein. Bars represent SD.
doi:10.1371/journal.pone.0016007.g006
Figure 7. Formation of EVs in various human malignant tumor
cell lines. Human gastric carcinoma N-87 (A) and flavopiridol-resistant
breast cancer MCF-7/FLV1000 cells (B) were fixed and co-reacted with
antibodies to ABCG2 (f), ZO-1 (b) and ERM complex (c and g) as detailed
in Materials and Methods. Cells were then examined with a Zeiss
inverted Cell-Observer microscope at a magnification of 6400. The
merged images including nuclei stained with DAPI were generated
using Cell-Observer software. BF indicates bright field mode. Continuous
arrows denote the localization of EVs markers (either ABCG2 or ERM
complex), whereas dashed arrows indicate TJ localization.
doi:10.1371/journal.pone.0016007.g007
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cytoskeletal elements; actin filaments were predominantly concen-
trated in a thin network around the EVs membrane, whereas
microtubules radiated out from EVs. Thus, it is likely that
microtubules are oriented with their minus end towards the apical
domain (i.e. EVs), as found for other polarized epithelial cells
including MDCK and WIF-B9 cells, and that they play a key role
in polarized trafficking of transmembrane proteins [27]. Third, not
only was the localization pattern of actin filaments and
microtubules in MCF-7/MR cells similar to that reported for
WIF-B9 and HepG2 cells, the impact of treatment with CytD and
nocodazole, was found to be identical in MCF-7/MR cells and
hepatoctyes [15,16]. Forth, it is yet unclear how exactly actin
filaments participate in apical trafficking, cycling and endocytosis
of ABC transporters in the liver and secretory epithelia including
breast epithelium. However, a study implicating actin participa-
tion in targeting and/or maintenance of apical localization of ABC
transporters involves knockout mice in which the radixin gene,
encoding for the dominant ERM protein in the liver, was
eliminated by targeted disruption [38]; hence, elimination of
radixin, which is localized at the bile canalicular membrane,
resulted in progressive dilation of canaliculi, decreased microvilli
and most importantly jaundice, due to impaired apical trafficking
of ABCC2 and disappearance of other characteristic canalicular
ABC transporters. Consistently here, ERM proteins perfectly co-
localized with ABCG2 in the EVs membrane border and in cell-
cell attachment zones of MCF-7/MR and parental MCF-7 cells.
This is a novel observation as no direct interaction between
ABCG2 and ERM proteins was reported to date [39]. We
therefore propose that the possible interaction between structural
proteins of the ERM complex and ABC transporters is essential for
their proper localization, retention and function at the EVs
membrane. Hence, EVs localization of ERM proteins may be a
prerequisite for vesicular biogenesis and function of ABC
transporters.
Ectopic overexpression of ABCB1 and ABCC2 in transfectant
MCF-7/MR cells resulted in a unique pattern of hemi-vesicular
distribution of these MDR pumps in the EV membrane.
Specifically, immunofluorescence microscopy revealed that
ABCB1 and ABCC2 localized in only one half of the EV
membrane, whereas endogenous ABCG2 was equally distributed
in the EV membrane. This important observation is in complete
concordance with a previous study in which WIF-B9 cells were
transfected with YFP-ABCB11, thereby resulting in the same
staining pattern referred to as ‘‘hemi-canaliculi’’ [28]. Likewise,
our present hemi-vesicular staining pattern of ABCB1 and
ABCC2 could be explained by the fact that EVs are formed and
shared by two (or more) attached cells, one of which was
successfully transfected with the ABC transporter gene, whereas its
neighbor counterpart was not, due to the relatively low
transfection efficiency (,10–15%). Thus, the EV membrane
presumably originates from the plasma membrane where each
attached cell contributes its relative share of the EV membrane
and its transmembrane proteins.
The current study and our previous reports [8,12] provide
evidence supporting the conclusion of the gradual development and
biogenesis of EVs from early and premature vesicular structures to
mature EVs: 1) Previously we have shown that the membrane of
both premature and mature EVs is a lipid bilayer with multiple
microvilli-like invaginations protruding into the intravesicular
lumen, which are likely to increase the vesicular membrane surface
area, and hence transmembrane fluxes of cytotoxic agents [8]. 2)
ZO-1 was observed precisely at the border between EVs-forming
attached cells, even at the early stages of EVs formation, when
ABCG2 was present only at cell-cell attachment zones. 3) ABCG2-
rich crucifer-like structures forming at cell-cell attachment zones co-
localized with ERM proteins and were readily capable of
concentrating cytotoxic agents that are established ABCG2
substrates including topotecan, imidazoacridinones, methotrexate,
MR, Hoechst 33342 and the B2-vitamin riboflavin just like mature
EVs. These cumulative evidences indicate that premature EVs
structures are indeed early EVs. Following ABCG2-dependent
intravesicular concentration of various substrates, these early EVs
structures fill up with fluids, hence leading to gradual increase in
intravesicular volume, thereby resulting in the formation of mature
oval-shaped EVs. Thus, in mature EVs, ABCG2 localizes
Figure 8. Inhibition of cell growth by topotecan and its
accumulation in EVs. (A) MCF-7/MR cells were grown in riboflavin-
deficient medium for 7 days on dishes containing cover glass bottom.
Then, cells were incubated with topotecan (5mM) for 24hr at 37uC in the
presence (d–f) or absence (a–c) of FTC (10mM). Control cells were
cultured in drug-free and riboflavin-deficient medium (g–i). Intravesi-
cular accumulation of topotecan was analyzed as described in Materials
and Methods. Arrows indicate the localization of EVs that lack or contain
topotecan. (B) MCF-7 and MCF-7/MR cells were grown for 3 days,
exposed to various concentrations of topotecan for 72h in the absence
or presence of FTC (10mM), following which the cytotoxic effect was
determined by the colorimetric XTT assay. Shown are the means of
three independent experiments, each performed in triplicates 6 SD.
Topotecan IC50 values in MCF-7 and MCF-7/MR cells were 1.0460.06
and 25.562.6, respectively.
doi:10.1371/journal.pone.0016007.g008
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EVs in a zipper-like manner precisely at the border of cells. This
ABCG2 protein level-dependent biogenesis process explains the
observed differences between the multiple, mature EVs observed in
MCF-7/MR cells and the rare, small and irregularly shaped EVs of
parental MCF-7 cells (as shown in Figure 4); this is in good
agreement with the differential targeting of the ectopically
overexpressed ABCG2-EGFP in parental MCF-7 and MCF-7/
MR cells (Supplementary Figure S2).
The current study constitutes a novel modality of chemoresis-
tance to multiple anticancer drugs mediated by EVs in breast
cancer cells. The possible existence of such multidrug-concentrat-
ing compartments in tumor-derived specimens, allowing seques-
tration of anticancer drugs away from their intracellular
pharmacological targets is underway in our laboratory, and may
have important implications for the overcoming of MDR
phenomena in cancer chemotherapy. Since ABCG2 transport
inhibitors fully restored drug sensitivity to various anticancer
drugs, this could be potentially applied in MDR tumors with
ABCG2-rich EVs. Inhibition of EVs biogenesis could be an
alternative approach; our preliminary studies using specific
inhibitors of the PI3K-Akt signaling axis (e.g. LY294002), reveal
a marked decrease in both the number of EVs and their volume
(data not shown). ABCG2 associated with the EVs membrane is
presumably retracted to the intracellular compartment, thereby
resulting in EVs that are unable to concentrate endogenously
Table 1. Multiple anticancer drug concentrative capacity of EVs.
Fluorescent compound Concentration (mM) Accumulation in EVs
Inhibition of accumulation
in EVs
a
Topotecan 5 ++
Imidazoacridinones C-1371 5 ++
C-1492 5 ++
C-1309 5 ++
C-1336 5 ++
C-1633 5 ++
C-1266 5 2 NS
Fluorescein-methotrexate 10 ++
Hoechst 33342 10 ++
Mitoxantrone 20 ++
Riboflavin
b 20 ++
a-10mM FTC were used to block ABCG2-dependent drug transport.
b-Not cytotoxic.
NS-Not a substrate.
doi:10.1371/journal.pone.0016007.t001
Figure 9. A proposed model of EVs structure and function. Shown is an EV formed between two attached MCF-7/MR cells. The EV is
structurally reinforced by an actin cytoskeleton. TJ proteins including occludin and ZO-1 (indicated by the dashed line surrounding the vesicles) seal
the EV to the extracellular milieu and to the surrounding cells. ABCG2 is highly expressed on the EV membrane, but not on the cell membrane facing
the medium or neighbor cells. ABCG2-rich EVs highly concentrate multiple cytotoxic agents including topotecan, methotrexate, imidazoacridinones,
Hoechst 33342 and MR [8] as well as the B2-vitamin riboflavin [12]. Just like ABCG2, ABCB1 and ABCC2 are also differentially targeted to the EV
membrane, whereas ABCC1, ABCC3 and PCFT are localized to the cell membrane. Na
+/K
+ ATPase is present at the cell membrane. ERM proteins,
which are highly targeted to the EV surface, presumably anchor these ABC transporters to the actin cytoskeleton.
doi:10.1371/journal.pone.0016007.g009
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Materials and Methods
Chemicals
Cytochalasin D (CytD), nocodazole, Hoechst 33342, fumitre-
morgin C (FTC), MR, topotecan, riboflavin, DAB, 39-amino 99-
ethyl carbazole (AEC), hematoxylin, Triton X-100 and DAPI
were purchased from Sigma-Aldrich (St. Louis, MO). Rhodamine-
phalloidin and fluorescein-methotrexate were from Invitrogen
(Carlsbad, CA). Imidazoacridinones were synthesized by Prof. M.
Cholody, B. Horowska and M. Konieczny and kindly provided by
Prof. A. Skladanowski, Gdansk University, Gdansk, Poland.
Tissue culture
Human breast cancer MCF-7 cells, their MR-resistant subline
MCF-7/MR as well as flavopiridol-resistant MCF-7/FLV1000
cells were grown as described previously [8]. Prior to vesicular
drug accumulation experiments, cells were grown in custom-made
riboflavin-deficient RPMI-1640 medium (Biological Industries,
Beth-Haemek, Israel) supplemented with 10% dialyzed fetal calf
serum (Invitrogen, Carlsbad, CA), glutamine and antibiotics.
Immunohistochemistry
MCF-7/MR cells (2610
4cell/2ml) were seeded in 24-well plates
and incubated for 4 days at 37uC. Immunohistochemical analysis
with anti-ABCG2 monoclonal antibody BXP-53 (1:100 dilution)
or with a polyclonal antibody directed to the b-subunit of Na
+/K
+
ATPase (GERK; 1:100 dilution) was performed as described
previously [12]. Color development was then carried out using
either 0.6 mg/ml DAB or 0.4mg/ml AEC in a buffer solution
containing 0.1M sodium acetate pH 4.7 and 0.02% H2O2. After
counterstaining of nuclei with hematoxylin, cells were examined
with a Leica inverted microscope using a bright field mode.
Immunofluorescence studies
Cells were seeded (5610
3 cells/2ml) in 24-well plates on sterile
glass coverslips and incubated for 7 days at 37uC. Cells were
processed with an identical staining protocol as described above (see
Immunohistochemistry microscopy) with the following modifications: first,
BXP-21 served as the primary ABCG2-specific monoclonal
antibody. TJ proteins were visualized using either rabbit-anti-
occludin antibody or a mouse anti-ZO-1 monoclonal antibody
(1:25, Invitrogen, Carlsbad, CA). The ERM protein complex was
visualized using rabbit monoclonal anti-ERM antibody (1:500
dilution, Epitomics, Burlingame, CA), which detects all three ERM
proteins. Second, FITC-conjugated donkey anti-mouse IgG or
rhodamine red-conjugated donkey anti-rabbit antibody (1:100
dilution, Jackson ImmunoResearch Laboratories, West Grove, PA)
served as the secondary antibodies. Third, cell nuclei were
counterstained with the DNA dye DAPI (0.5mg/ml) during the
incubation with the secondary antibody. Finally, for F-actin and b-
tubulin staining, cells were permeabilized with 0.1% Triton-X-100 in
PBS for 10 minand immunoreacted as described above. To visualize
F-actin, rhodamine phalloidin was added during the last 20 min of
incubation with the secondary antibody. Microtubules were followed
using mouse monoclonal antibody to b-tubulin (at 1:200 dilution,
Sigma). After four washes with PBS, coverslips were mounted onto
glass slides using Fluoromount-G (Southern Biotechnology Associ-
ates, Birmingham, AL) and examined using either a Leica inverted or
Zeiss inverted Cell-Observer or a confocal Zeiss LSM 510 META
microscope. Merged images were obtained using either the Leica
software or the AxioVision program (Zeiss, version 4.7).
Live cell imaging
MCF-7/MR cells were seeded in 24-wells plates on sterile glass
coverslips (5610
3cells/2ml) or in dishes containing cover glass
bottom (3610
4cells/2ml; World Precision Instruments) and grown
in riboflavin-containing or -lacking RPMI-1640 medium for at
least 72 hr prior to drug addition. Cells were then incubated either
with CytD (10mg/ml) for 30 min or with various chromophoric
cytotoxic drugs (Table 1) for 24 hr at 37uC. In all live imaging
microscopy experiments, cells were washed thrice with PBS,
resuspended in PBS supplemented with 1mM CaCl2, 1mM MgCl2
and 10mM D-glucose and random colonies were analyzed using
Zeiss inverted Cell-Observer microscope using the following filters:
phase mode, HE GFP (excitation and emission at 470 and
525 nm, respectively) or DAPI mode (excitation and emission at
365 and 445 nm, respectively) at a magnification of 6200–6630.
Subcellular localization of MDR transporters and PCFT
(SLC46A1)
MCF-7/MR cells were grown in 24-well plates containing glass
coverslips. Following 4 days of growth, monolayer cells were
transiently transfected using the jetPEI transfection reagent
(Polyplus-transfection Inc. New York, USA), according to the
manufacturer’s instructions. The following constructs were used:
pcDNA3 harboring ABCC1, ABCC2 or ABCC3; pcDNA3.1
harboring Myc-tagged PCFT [23] and pHAMDR1/WT con-
struct (AddGene). Forty to forty eight hr after transfection, cells
were fixed with 4% formaldehyde for 20 min and reacted with
specific antibodies as described in Immunofluorescence Studies.I n
addition, cells were stably transfected with a pcDNA3 harboring
ABCC2 or pEGFP-ABCG2 N1 construct (kindly provided by
Prof. L. Homolya) [40], using the same protocol and grown
continuously in selective medium containing 1mg/ml G418.
Immunofluorescence microscopy studies exploring the
polarity of MCF-7/MR cells
MCF-7/MR cellswere grown and transiently transfected with GPI-
CFP and VSVG-YFP constructs (generously provided by Prof. D.
C a s s e l ,T e c h n i o n ,I s r a e l ) .T ov i s u a l i ze VSVG, following transfection,
cells were incubated for 18h at 40uC and transferred to 32uC
for 2h prior to fixation. ABCG2 was visualized using BXP-53
antibody. Cellswere then analyzed usingZeissinverted Cell-Observer.
Western blot analysis
ABCG2 and ERM protein levels, as normalized to Na
+/K
+-
ATPase, were determined by Western blot using anti-ABCG2
(BXP-53; 1:3,000 dilution), anti-ERM (at 1:500 dilution) and anti-
Na
+/K
+-ATPase (KETTY at 1:3000 dilution) antibodies, respec-
tively, as described previously [8].
Cytotoxicity assay. Four to five hundred parental MCF-7
and MCF7/MR cells were seeded (90ml/well) in 96-well plates, in
a riboflavin-deficient medium and grown for 3 days to allow for
the formation of EVs. Cells were then subjected to increasing
concentrations of topotecan and incubated for 72h in the absence
or presence of the ABCG2 transport inhibitor FTC (10 mM). The
cytotoxic effect was determined using a colorimetric XTT cell
proliferation kit (Biological Industries, Beth-Haemek, Israel).
Flow cytometric analysis of surface ABCG2 expression in
viable cells
One million cells were washed thrice in PBS and suspended in
100ml PBS containing 1% BSA. Then, cells were incubated either
with or without a PE-conjugated anti-human ABCG2 monoclonal
antibody 5D3 (0.25mg/100ml; eBioscience, San Diego, CA). After
ABCG2-Rich Vesicles Mediating MDR
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water, washed thrice with PBS, resuspended in ice-cold PBS
containing 1% BSA and cellular fluorescence was determined using
a FACSCalibur flow cytometer(BD Bioscience). FL2-Hexcitation of
PE-labeled cells was performed at550nm and emission wascollected
at 574nm. Data analysis was performed using FCSexpress software.
Supporting Information
Figure S1 ABCG2 specifically localizes to the EVs mem-
brane in MCF-7 cells. MCF-7 cells were grown and analyzed by
immunofluorescence microscopy as described in Figure 1 legend.
ABCG2 (red fluorescence), ZO-1 (green fluorescence), nuclei (blue
fluorescence). Arrows denote the location of the EVs.
(TIF)
Figure S2 EGFP-ABCG2 overexpression in transfectant
MCF-7 and MCF-7/MR cells results in its differential
targeting. MCF-7 (A–C) and MCF-7/MR cells (D–F) were stably
transfected with the pEGFP-ABCG2 N1 construct as described in
Materials and Methods, grown in riboflavin-deficient medium for at
least 4 days prior to fluorescence microscopy and studied using a
Leica microscope (6200). Arrows denote the location of ABCG2-
EGFP either in ABCG2-rich EVs (D–F) or at the cell membrane
(A–C). Untransfected MCF-7/MR cells (G–H) were grown and
analyzed by immunofluorescence as in Figure 1. Continuous arrows
denote the location ABCG2 in cells that do not form EVs. Note that
ABCG2 in the EVs-forming cells is predominantly localized to the
EVs (dashed arrow), with no residual signal in ER or cell membrane.
(TIF)
Figure S3 Localization of endogenous Na
+/K
+ ATPase in
MCF-7/MR cells. Immunohistochemistry: MCF-7/MR cells were
reacted either with BXP-53 (A and D) or with anti-b subunit of
Na
+/K
+ ATPase polyclonal antibody (GERK; panels B and E),
followed by HRP-conjugated goat anti-rat or anti-rabbit IgG,
respectively, and color development was carried out using either
the red chromogen AEC (A–C) or the brown chromogen DAB
(D–F). As a control, cells were reacted solely with secondary
antibodies including HRP-conjugated goat anti-rabbit (C) or anti-
rat (F). Cells were then examined using a Leica microscope at
6400 magnification at a bright field mode. The continuous arrows
denote the location of EVs, whereas the dashed arrows point to the
cell membrane containing Na
+/K
+ ATPase but not ABCG2.
Immunofluorescence: MCF-7/MR cells were reacted either with BXP-
21 (G) or with an anti-Na
+/K
+ ATPase antibody (H). Nuclei were
counterstained with DAPI. Stained cells were then analyzed using
a laser scanning confocal microscope (Zeiss LSM 510 META). A
merged image (I) was obtained using the Zeiss LSM software.
Na
+/K
+ ATPase localization to the membrane of EVs was
examined by performing Z-stack sections creating 15 optical slices
(0.5mm thick each). Z-sectioning images of the indicated area in I
(white square) is shown in panel J, where the horizontal and the
vertical lines indicate the exact position of the Z-stack.
(TIF)
Figure S4 Large Gaussian distribution of surface
ABCG2 expression in MCF-7/MR and A549/K1.5 cells.
Live MCF-7/MR and A549/K1.5 cells were incubated either
with (B and D, respectively) or without (A and C, respectively) PE-
conjugated anti-human ABCG2 antibody (5D3) as described in
Materials and Methods. Shown are representative results summa-
rized as dot graphs. Y- axis presents the side scatter count, whereas
the X-axis represents ABCG2 fluorescence. Geometric means of
MCF-7/MR and A549/K1.5 cell were estimated as 331.8615.0
and 689.4646.2, respectively, whereas geometric means of auto-
fluorescence were approximately 2.060.2 in both cell lines.
(TIF)
Video S1 Localization of ABCG2 and F-actin in MCF-7/
MR cells. Cells were grown for 7 days, fixed with 4%
formaldehyde and permeabilized using Triton-X-100. Then, cells
were reacted with anti-ABCG2 antibody (BXP-21, green fluores-
cence) as well as with rhodamine phalloidin which binds to actin
filaments (red fluorescence). Nuclei were stained with DAPI (blue
fluorescence). Slides were analyzed by Z-stack sections creating 12
optical slices (0.5mm thick each) using a laser-scanning confocal
microscope (Zeiss LSM 510 META) at 6630 magnification. The
merged image of all obtained slices was animated into a video
using LSM image browser software (Zeiss Inc.).
(AVI)
Video S2 Localization of ABCG2 and Na
+/K
+ ATPase in
MCF-7/MR cells. Cells were grown for 7 days, fixed with 4%
formaldehyde and reacted with anti-ABCG2 antibody (BXP-21,
green fluorescence) as well as with an anti-Na
+/K
+ ATPase
antibody (GERK, red fluorescence). Cells were then analyzed by
Z-stack sections creating 15 optical slices (0.5mm thick each) using
a laser-scanning confocal microscope (Zeiss LSM 510 META) at a
magnification of 6630. The merged image of all obtained slices
was animated into a video using LSM image browser software
(Zeiss Inc.).
(AVI)
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